News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,
Shares of Hims & Hers Health (NYSE: HIMS) are imploding on Monday, down 32% as of 3:03 p.m. ET. The drop comes as the S&P 500 ...
In its first-quarter 2025 investor letter, Carillon Scout Mid Cap Fund highlighted stocks such as Hims & Hers Health, Inc.
Meanwhile, Novo had agreed supply deals with Hims and several of its larger rivals. The idea was to give their existing ...
LOS ANGELES, June 23, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("H ...
What if I purchased Hims & Hers securities? If you incurred significant losses and want to determine if you are eligible to participate in the potential class action or to seek a recovery of your ...
Telemedicine company Hims & Hers Health has been one of the hottest healthcare stocks in recent memory. Changes at ...
MarketBeat on MSN1d
Why Hims & Hers Stock Could Be a Multi-Bagger in the MakingIt’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.
Hims & Hers Health (NYSE:HIMS) recently announced the introduction of affordable access to Wegovy, a significant move aimed at improving obesity treatment options. This, along with strong Q1 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback